搜索
Search
这是描述信息

中文(wén)

News Center

/
News Center
The birth of Likang V-01 indicates a new leap in R&D and innovation
The
2022-11-29
View details
Expert consensus: Livzon Antiviral Granules are recommended for mild and common infections of COVID-19
Expert
Expert consensus: Livzon Antiviral Granules are recommended for mild and common infections of COVID-19
2022-04-20
View details
Livzon Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) approved by China NMPA.
Livzon
View details
Employee Grievance Management System
Employee
View details
A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial
A
View details
Livzon Pharmaceutical Group was recognized as the National Enterprise Technology Center with High Scores
Livzon
Livzon Pharmaceutical Group was recognized as the National Enterprise Technology Center with High Scores
2022-04-20
View details
Livzon participated in the 39th Annual JP Morgan Medical Health Conference
Livzon
View details
Environmental，Social and Governance Report 2019
Environmental，Social
Since the new round of medical and health system reforms launched in China in 2009, a complete basic
medical insurance system has been gradually established and major health indicators of the residen
View details
Since the new round of medical and health system reforms launched in China in 2009, a complete basic
medical insurance system has been gradually established and major health indicators of the residen
Previous page
1
2
3
4
5
6

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China    Tel： 0756-8135888    

©2021 Livzon  Support：300.cn

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China  

©2021 Livzon   

 Support：300.cn